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Streszczenie
WstŒp: Rak rdzeniasty tarczycy zwykle jest rozpoznawany
w stadium bardziej zaawansowanego guza ni¿ raki zró¿ni-
cowane i czŒsto z przerzutami. Leczeniem z wyboru jest
ca‡kowite wyciŒcie tarczycy i regionalnych wŒz‡ów ch‡on-
nych. Skutecznoæ tych zabiegów bywa ograniczona, co
wi„¿e siŒ z agresywnoci„ choroby i jej zaawansowaniem
w momencie operacji. Utrzymuj„ce siŒ lub ponownie pod-
wy¿szone stŒ¿enia kalcytoniny (CT) i antygenu rakowo-p‡o-
dowego (CEA) wskazuj„ na obecnoæ resztkowej choroby lub
wznowŒ procesu. Jednak nie zawsze rutynowo wykony-
wane badania obrazowe (USG, TK, MRI, scyntygrafia MIBI)
prowadz„ do znalezienia ród‡a kalcytoniny. WiŒksz„ czu-
‡oæ wykazuje scyntygrafia DMSA, receptorów somatosta-
tynowych i pozytonowa tomografia emisyjna (PET).
Celem niniejszej pracy by‡a ocena przydatnoci badania PET
w celu zlokalizowania ognisk wznowy i/lub przerzutów
raka rdzeniastego u chorych z podwy¿szonymi stŒ¿eniami
kalcytoniny po leczeniu operacyjnym, u których rutynowy-
mi metodami nie znaleziono ogniska nowotworu.
Materia‡ i metody: Badanie PET z wykorzystaniem 18F-flu-
oro-2-deoksy-D-glukozy, po‡„czone z tomografi„ kompute-
row„ (18FDG-PET/CT), przeprowadzono w Zak‡adzie Medy-
cyny Nuklearnej Centrum Onkologii w Bydgoszczy miŒ-
dzy styczniem a padziernikiem 2004 roku. Badanie to wy-
konano u 5 chorych, u których obserwowano podwy¿szone
pooperacyjne stŒ¿enia kalcytoniny (164,0  > 2000,0 ng/l;
norma < 10,0 ng/l), a rutynowe badania obrazowe nie lokali-
zowa‡y podejrzanych ognisk.
Wyniki: U 4 sporód 5 chorych wykazano w tym badaniu
obecnoæ ognisk o zwiŒkszonym metabolizmie 18FDG, które
wskazywa‡y na umiejscowienie zmiany nowotworowej.
W jednym przypadku nie stwierdzono wyranego ogniska
wzmo¿onego metabolizmu znacznika, mimo wysokich stŒ-
¿eæ kalcytoniny. Rozpoznane ogniska zlokalizowane by‡y
w dwóch przypadkach na szyi i w ródpiersiu, w jednym
w p‡ucu i lewym nadnerczu, a w jednym na szyi i w w„tro-
bie. W wyniku przeprowadzonych powtórnych operacji,
u wszystkich chorych potwierdzono histopatologicznie pra-
wid‡owoæ rozpoznania, a w 3 przypadkach stwierdzono
obni¿enie stŒ¿eæ kalcytoniny i CEA, co wiadczy o skutecz-
noci leczenia chirurgicznego opartego na obrazach z ba-
dania PET/CT.
Wnioski: Pozytonowa tomografia emisyjna stanowi cenn„
metodŒ diagnostyki obrazowej w poszukiwaniu przerzutów
raka rdzeniastego tarczycy o trudnej do ustalenia lokalizacji.
(Endokrynol Pol 2006; 4 (57): 452455)
S‡owa kluczowe: rak rdzeniasty tarczycy, pozytonowa
tomografia emisyjna, przerzuty
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Abstract
Introduction: Medullary thyroid carcinoma (MTC) is usu-
ally more advanced at presentation than differentiated thy-
roid cancers and often has distant metastases. The primary
treatment of MTC is total thyroidectomy and regional lymph
node dissection. The efficacy of these procedures has been
limited by the aggressiveness of the disease and metastatic
spread at the time of surgery. Persistently elevated levels of
calcitonin (CT) and carcinoembryonic antigen (CEA) or their
increase postoperatively are indicative for residual or
recurrent disease. Conventional imaging methods such as
ultrasonography, computed tomography, magnetic reso-
nance imaging and MIBI scintigraphy usually fail to find
the source of calcitonin. Better imaging properties have been
shown by DMSA scintigraphy, somatostatin receptor scin-
tigraphy or by positron emission tomography (PET).
The aim of the study was to evaluate the diagnostic accura-
cy of PET for the localisation of occult MTC in patients after
surgery with increased concentrations of CT, in whom con-
ventional imaging procedures have not been successful.
Material and methods: The PET investigation using 18F-flu-
oro-2-deoxy-D-glucose combined with computed tomogra-
phy (18FDG-PET/CT) was performed at the Department of
Nuclear Medicine (Oncology Centre in Bydgoszcz) betwe-
en January and October 2004. In five patients with posto-
perative calcitonin ranging from 164 to > 2000 ng/l (normal
< 10 ng/l) no tumour lesions were found using other ima-
ging methods.
Results: In four of five cases, responsible lesions with a higher
metabolism of FDG, indicating MTC tissue (remnants or me-
tastases), were localised. In one patient no focus of FDG ac-
cumulation was found despite high CT concentration. PET
detected tumour manifestations in the neck and the me-
diastinum in two patients, in the lung and the left adrenal
gland in one case and in the neck and the liver in another
patient. As a result of surgery for the removal of a residual
tumour or metastases the accuracy of diagnosis was confir-
med by histopathology in all four cases and a decrease in
CT and CEA levels was observed in 3/4 cases. The metabo-
lic imaging findings by PET/CT ensured that the surgery
on these patients was successful.
Conclusions: For the detection of occult residual or meta-
static MTC lesions, 18FDG-PET is a valuable procedure in
imaging diagnostics.
(Pol J Endocrinol 2006; 4 (57): 452455)
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Introduction
Medullary thyroid carcinoma (MTC) is a neoplasm of
the thyroid parafollicular C cells that accounts for
58% of all thyroid cancers [1]. MTC produce calcito-
nin (CT), a specific marker, and carcinoembryonic an-
tigen (CEA), a non-specific tumour marker. MTC may
occur either sporadically or in a hereditary form as fa-
milial MTC including multiple endocrine neoplasia
type 2A or type 2B and isolated familial MTC [2]. Both
forms of MTC are characterised by relatively slow tu-
mour growth but early lymphatic metastatic spread.
Of the well differentiated thyroid carcinomas MTC is
the most aggressive, with survival rates of 4050% at
10 years [3]. Neck lymph node metastases are detec-
ted in at least 50% of patients, and metastases outside
the neck, in the liver, lungs or bones, are present ini-
tially in 20% of cases [1]. The primary treatment of MTC
is total thyroidectomy and bilateral lymph node dis-
section. Several studies have shown that survival in
patients with MTC is dependent upon the adequacy
of the initial surgical procedure. Unfortunately, even
with aggressive surgery, most patients with MTC do
not achieve normalisation of postsurgical serum CT
and CEA levels. Biochemical cure is obtained in only
2030% of patients with lymph node metastases, and
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rarely in patients with extensive lymph node involve-
ment or distant metastases [4].
In patients with persistently elevated or again in-
creased CT levels, the challenge to find the site of the
residual or recurrent disease, since surgical resection is
at the moment the only curative treatment. Tumour
localisation techniques include ultrasonography (US) of
the neck and liver, computed tomography or magnetic
resonance imaging (MRI) of the neck, chest and liver.
The scintigraphic studies used in the evaluation of MTC
such as 99mTc-sestamibi (MIBI), pentavalent 99mTc-dimer-
captosuccinic acid (DMSA), 123I/131I-metaiodobenzylgu-
anidine (MIBG), and somatostatin analogues labelled
with 111In (SRS) are poorly sensitive, especially for small
lesions [5]. 18F-fluoro-2-deoxy-D-glucose (FDG) positron
emission tomography (18FDG-PET), as a functional ima-
ging technique that relies on in vivo visualisation of le-
sional glucose metabolism, differs from conventional
imaging procedures [6]. FDG-PET scanning in patients
with MCT offers a potential approach to the detection
of recurrent or metastatic disease [79]. The aim of the
present study was to evaluate the diagnostic accuracy
of PET for the localisation of occult MTC in patients after
surgery with increased concentrations of CT, in whom
conventional imaging procedures have been failed.
Material and methods
PET investigation using 18F-fluoro-2-deoxy-D-glucose
combined with computed tomography (18FDG-PET/CT)
was performed at the Department of Nuclear Medicine
(Oncology Centre in Bydgoszcz) between January and
October 2004. In five patients (three women and two
men, aged 4383 years) with postoperative CT ranging
from 164.0 to > 2000.0 ng/l (normal < 10 ng/l), no tu-
mour lesions were found using other imaging methods.
All our patients had been diagnosed earlier using US of
the abdomen, computed tomography and MRI of the
neck and the chest and whole body SRS.
Results
In four of five cases the lesions responsible, with a hi-
gher metabolism of 18FDG indicating MTC tissue (rem-
nants or metastases), were localised. In one patient no
focus of FDG accumulation was found, despite high CT
and CEA concentrations. PET/CT detected tumour ma-
nifestations in the neck and the mediastinum in two
patients and in the neck and liver an another patient.
In a male with confirmed MEN2A syndrome [10] after
earlier right adrenalectomy, foci of increased metabo-
lism of 18FDG were identified in the lung and in the left
adrenal gland. In only one PET study the diameter of
a focus of 12 mm in the neck region was given precise-
ly. In another PET investigations only the localisation
of the MTC remnants and/or metastases, without infor-
mation concerning their diameters, was suggested by
radiology. On the basis of the results of histopathologi-
cal studies, the tissues removed were found in one case
to be a local recurrence in the neck and metastatic lymph
nodes. In other patients the source of CT and CEA were
the cervicomediastinal lymph nodes with neoplastic
infiltration of the capsule. Four of the patients investi-
gated underwent surgery for the removal of a residual
tumour or metastases. The accuracy of the diagnosis was
confirmed by histopathology in all four cases. Postope-
ratively, a significant decrease in CT and CEA levels was
observed in three cases.
Discussion
Conventional radiographic and radionuclide imaging
often fail to localise recurrent or metastatic medullary
thyroid carcinoma, resulting in poor outcome of the
disease. In the search for a more reliable method 18FDG-
-PET has been applied to detect MTC tissue, which has
a high potential for metastasis. Studies of the clinical
role of FDG-PET in the diagnosis and staging of recur-
rent and metastatic MTC have shown encouraging re-
sults. Musholt et al. [7] compared the accuracy of FDG-
PET with that of computed tomography and MRI scans
and found that PET imaging was more sensitive in the
detection of cervicomediastinal MTC metastases. A stu-
dy by Szakall et al. [8] suggested that FDG-PET was
a highly sensitive method for localising metastases in
MTC patients with elevated postsurgical CT levels. PET
demonstrated more lesions in the neck and the media-
stinum than were found by other imaging methods, but
it failed to detect many small lesions in the lung and
liver. The lack of attenuation correction in their study
and the relatively low sensitivity of PET for small pul-
monary metastases were probable reasons for a decre-
ased tumour detection rate in the lung and liver. Ho-
wever, in contrast to this, we found on PET scans one
metastatic focus in the liver in one case and one lesion
of increased FDG metabolism in the lung in an another
patient. The metabolic imaging findings by PET in the-
se patients have been observed to result in a higher bio-
chemical cure rate obtained by further surgery.
A recent prospective study of 26 patients reported
that 18FDG-PET is superior to conventional imaging
techniques for the detection of recurrent or metastatic
MTC [9]. The sensitivity was 96% for FDG-PET, 41%
for 111In-SRS, 57% for DMSA, and 87% for morphologi-
cal imaging (US, computed tomography, MRI) combi-
ned with bone scintigraphy. In our study positive
18FDG-PET findings led to more radical surgical inte-
rvention in four out of five patients. In three of them
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meticulous lymph node dissection and the removal of
distant metastases resulted in a decrease in CT and CEA
levels, which are sensible markers of active MTC. Al-
though the diagnosis of disseminated MTC was confir-
med by histopathology of the removed tissues in all four
cases, it was suggested that undiagnosed foci of the di-
sease remained in one patient without a postsurgical
decrease in CT and CEA. Interestingly, retrospective
analysis of computed tomography and MRI scans re-
vealed the presence of MTC foci in the neck, which were
later found in one case by the PET study.
As the most recent nuclear medicine imaging pro-
cedure 18FDG-PET appears to be a promising diagno-
stic technique for the detection of recurrent or metasta-
tic MTC. Despite the high cost and lack of availability
of PET, this method may serve to increase the cure rate
and to prolong survival in patients with MTC.
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